FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

4-Component Strep

Drug and asset intelligence for 4-Component Strep with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Stage: Development stage unavailable

Sponsor company

GSK →

Mechanism of action

Vaccine

Recent signals(1)

ClinicalAugust 13, 2026

GSK Initiates First Human Trial for 4-Component Strep A Vaccine

GlaxoSmithKline has initiated Phase 1 clinical trial to evaluate the safety, reactogenicity, and immunogenicity of two novel formulations of a 4-component Strep A vaccine in healthy young adults aged 18 to 25.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Infectious Disease →

Therapeutic areas

Infectious Disease →

Vaccine →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.